Nkarta Competitors

Nkarta (NASDAQ:NKTX) and Biohaven Pharmaceutical (NYSE:BHVN) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, dividends, institutional ownership, profitability and valuation.

Valuation and Earnings

This table compares Nkarta and Biohaven Pharmaceutical's revenue, earnings per share and valuation.

Profitability

This table compares Nkarta and Biohaven Pharmaceutical's net margins, return on equity and return on assets.

Institutional and Insider Ownership

77.1% of Nkarta shares are owned by institutional investors. Comparatively, 99.4% of Biohaven Pharmaceutical shares are owned by institutional investors. 19.1% of Biohaven Pharmaceutical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Nkarta and Biohaven Pharmaceutical, as provided by MarketBeat.com.

Nkarta currently has a consensus price target of $59.00, suggesting a potential upside of 64.90%. Biohaven Pharmaceutical has a consensus price target of $96.7273, suggesting a potential upside of 28.61%. Given Nkarta's stronger consensus rating and higher possible upside, research analysts plainly believe Nkarta is more favorable than Biohaven Pharmaceutical.

Summary

Nkarta beats Biohaven Pharmaceutical on 4 of the 7 factors compared between the two stocks.

Nkarta (NASDAQ:NKTX) and Sage Therapeutics (NASDAQ:SAGE) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, dividends, institutional ownership, profitability and valuation.

Valuation and Earnings

This table compares Nkarta and Sage Therapeutics' revenue, earnings per share and valuation.

Nkarta has higher earnings, but lower revenue than Sage Therapeutics.

Profitability

This table compares Nkarta and Sage Therapeutics' net margins, return on equity and return on assets.

Institutional and Insider Ownership

77.1% of Nkarta shares are owned by institutional investors. 4.8% of Sage Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Nkarta and Sage Therapeutics, as provided by MarketBeat.com.

Nkarta currently has a consensus price target of $59.00, suggesting a potential upside of 64.90%. Sage Therapeutics has a consensus price target of $86.6875, suggesting a potential upside of 16.02%. Given Nkarta's stronger consensus rating and higher possible upside, research analysts plainly believe Nkarta is more favorable than Sage Therapeutics.

Summary

Nkarta beats Sage Therapeutics on 6 of the 9 factors compared between the two stocks.

Nkarta (NASDAQ:NKTX) and Hutchison China MediTech (NASDAQ:HCM) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, dividends, institutional ownership, profitability and valuation.

Valuation and Earnings

This table compares Nkarta and Hutchison China MediTech's revenue, earnings per share and valuation.

Nkarta has higher earnings, but lower revenue than Hutchison China MediTech.

Profitability

This table compares Nkarta and Hutchison China MediTech's net margins, return on equity and return on assets.

Institutional and Insider Ownership

77.1% of Nkarta shares are owned by institutional investors. Comparatively, 33.5% of Hutchison China MediTech shares are owned by institutional investors. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Nkarta and Hutchison China MediTech, as provided by MarketBeat.com.

Nkarta currently has a consensus price target of $59.00, suggesting a potential upside of 64.90%. Hutchison China MediTech has a consensus price target of $40.00, suggesting a potential upside of 34.45%. Given Nkarta's higher possible upside, research analysts plainly believe Nkarta is more favorable than Hutchison China MediTech.

Summary

Nkarta beats Hutchison China MediTech on 3 of the 4 factors compared between the two stocks.

Nkarta (NASDAQ:NKTX) and I-Mab (NASDAQ:IMAB) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, dividends, institutional ownership, profitability and valuation.

Valuation and Earnings

This table compares Nkarta and I-Mab's revenue, earnings per share and valuation.

Nkarta has higher earnings, but lower revenue than I-Mab.

Profitability

This table compares Nkarta and I-Mab's net margins, return on equity and return on assets.

Institutional and Insider Ownership

77.1% of Nkarta shares are owned by institutional investors. Comparatively, 16.6% of I-Mab shares are owned by institutional investors. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Nkarta and I-Mab, as provided by MarketBeat.com.

Nkarta currently has a consensus price target of $59.00, suggesting a potential upside of 64.90%. I-Mab has a consensus price target of $70.00, suggesting a potential upside of 19.82%. Given Nkarta's higher possible upside, research analysts plainly believe Nkarta is more favorable than I-Mab.

Summary

Nkarta beats I-Mab on 3 of the 4 factors compared between the two stocks.

Nkarta (NASDAQ:NKTX) and Arena Pharmaceuticals (NASDAQ:ARNA) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, dividends, institutional ownership, profitability and valuation.

Valuation and Earnings

This table compares Nkarta and Arena Pharmaceuticals' revenue, earnings per share and valuation.

Arena Pharmaceuticals has higher revenue and earnings than Nkarta.

Profitability

This table compares Nkarta and Arena Pharmaceuticals' net margins, return on equity and return on assets.

Institutional and Insider Ownership

77.1% of Nkarta shares are owned by institutional investors. Comparatively, 89.7% of Arena Pharmaceuticals shares are owned by institutional investors. 3.1% of Arena Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Nkarta and Arena Pharmaceuticals, as provided by MarketBeat.com.

Nkarta currently has a consensus price target of $59.00, suggesting a potential upside of 64.90%. Arena Pharmaceuticals has a consensus price target of $92.80, suggesting a potential upside of 38.90%. Given Nkarta's higher possible upside, research analysts plainly believe Nkarta is more favorable than Arena Pharmaceuticals.

Summary

Arena Pharmaceuticals beats Nkarta on 4 of the 7 factors compared between the two stocks.

Nkarta (NASDAQ:NKTX) and Agios Pharmaceuticals (NASDAQ:AGIO) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, profitability, earnings, institutional ownership and dividends.

Institutional & Insider Ownership

77.1% of Nkarta shares are held by institutional investors. Comparatively, 92.9% of Agios Pharmaceuticals shares are held by institutional investors. 3.2% of Agios Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares Nkarta and Agios Pharmaceuticals' net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Nkarta and Agios Pharmaceuticals' revenue, earnings per share and valuation.

Nkarta has higher earnings, but lower revenue than Agios Pharmaceuticals.

Analyst Ratings

This is a summary of current ratings and price targets for Nkarta and Agios Pharmaceuticals, as provided by MarketBeat.

Nkarta currently has a consensus target price of $59.00, suggesting a potential upside of 64.90%. Agios Pharmaceuticals has a consensus target price of $64.6364, suggesting a potential upside of 17.12%. Given Nkarta's stronger consensus rating and higher possible upside, equities analysts clearly believe Nkarta is more favorable than Agios Pharmaceuticals.

Summary

Nkarta beats Agios Pharmaceuticals on 5 of the 9 factors compared between the two stocks.